-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Adaptive Biotechnologies, Maintains $21 Price Target

Benzinga·05/06/2026 14:49:45
Listen to the news
Guggenheim analyst Subbu Nambi reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $21 price target.